Laurence Klotz

Sunnybrook Health Science Centre — Canada

Medicine · Health Sciences

86h-index34.5kcitations825works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(447), Prostate Cancer Diagnosis and Treatment(420), Bladder and Urothelial Cancer Treatments(115), Hormonal and reproductive studies(79), Cancer, Lipids, and Metabolism(71)

Publications823 total

Micro-ultrasound for prostate cancer
Nature Reviews Urology·2025
Imaging in focal therapy: advanced ultrasound imaging and mpMRI—a comprehensive review
Prostate Cancer and Prostatic Diseases·2025
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis—Reply
JAMA·2025· 2 cited
SIU-ICUD: Localized Prostate Cancer
Société Internationale d’Urologie Journal·2025· 1 citedOpen Access
Erratum for: Effect of <sup>18</sup>F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial
Radiology·2025
2901 Identifying Intermediate Risk Prostate Cancer Patients Appropriate for Active Surveillance using Recursive Partitioning Analysis.
Radiotherapy and Oncology·2025
Abstract 1969: Advancing metastatic prostate cancer diagnostics: STEAP1-based imaging flow cytometry for circulating tumor cell detection and characterization
Cancer Research·2025
MP10-12 PROGNOSTIC VALUE OF MR VISIBILITY/INVISIBILITY IN MEN ON ACTIVE SURVEILLANCE
The Journal of Urology·2025
MP06-19 DEEP LEARNING PROSTATE SEGMENTATION MODULE TO ASSIST IN MRI-GUIDED TRANSURETHRAL ULTRASOUND (TULSA) TREATMENT PLANNING: VALIDATION STUDY AND REAL-WORLD PERFORMANCE
The Journal of Urology·2025
A0077 – CAPTAIN randomized controlled trial of TULSA against radical prostatectomy for intermediate-risk prostate cancer: Design, enrollment update and best practices for successful recruitment
European Urology·2025
CAPTAIN RANDOMIZED CONTROLLED TRIAL OF TULSA AGAINST RADICAL PROSTATECTOMY FOR INTERMEDIATE-RISK PROSTATE CANCER: DESIGN AND RECRUITMENT UPDATE
Urologic Oncology Seminars and Original Investigations·2025
Association of marginalization and PSMA-PET in prostate cancer
Canadian Urological Association Journal·2025· 1 citedOpen Access
Defining subgroups of patients with intermediate risk prostate cancer for whom active surveillance is safe.
Journal of Clinical Oncology·2025
A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.
Journal of Clinical Oncology·2025
Prognostic value of MR visibility/invisibility in men on Active Surveillance
Prostate Cancer and Prostatic Diseases·2025· 4 cited
The Metformin Active Surveillance Trial for Low-Risk Prostate Cancer
SSRN Electronic Journal·2025Open Access
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men
Journal of the National Comprehensive Cancer Network·2024· 2 citedOpen Access
Prognostic value of MR visibility/invisibility in men on Active Surveillance
2024Open Access
The use of focal therapy for the treatment of prostate cancer in Canada
Canadian Urological Association Journal·2024· 2 citedOpen Access
VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer
European Urology·2024· 16 citedOpen Access
page 1 of 42Next →

Frequent Co-authors

Neil Fleshner(10), Robert K. Nam(7), Caroline M. Moore(6), Arnauld Villers(5), Joseph L. Chin(5), Andrew Loblaw(5), John Trachtenberg(5), Steven A. Narod(5), Masoom A. Haider(5), Linda Sugar(5), Veeru Kasivisvanathan(4), Danny Vesprini(4), Peter C. Albertsen(4), Peter R. Carroll(4), Antti Rannikko(3), Samir S. Taneja(3), Peter A. Pinto(3), Mark Emberton(3), Liying Zhang(3), Alexandre Mamedov(3)